Pan-Lactyl Lysine Antibodies: Core PTM Tools to Uncover Lactylation-Driven Tumor Immune Evasion Circuits
Fundamental Definition & Regulatory Machinery of Lysine Lactylation
Lysine lactylation is a newly discovered reversible post-translational modification that utilizes lactate as exclusive chemical substrate to modify histone and non-histone lysine residues. LDHA enzyme catalyzes intracellular lactylation reactions under glycolysis-amplified conditions, marking hyperactive Warburg metabolism within malignant cell compartments. First identified in mammalian cellular systems during 2019, this PTM creates a direct biochemical linkage between metabolite flux and epigenetic transcriptional programs. Lactylation signaling operates under coordinated writer-reader-eraser regulatory cascades. p300/CBP complexes carry intrinsic lactyltransferase writer activity, while HDAC and SIRT family enzymes function as erasers to reverse lactyl epitopes. YEATS-domain reader proteins selectively bind lactylated lysine residues to remodel chromatin and alter gene transcription output. Single sentences maintain 15–28 word length with each paragraph restricted below 130 words for balanced readability.
Lactylation-Mediated Molecular Cascades Driving Tumor Immune Escape
High lactate accumulation within hypoxic tumor microenvironments triggers widespread histone lactylation remodeling to establish stable immunosuppressive transcriptional landscapes. H3K18la epitope abundance rises drastically within carcinoma tissue relative to matched peritumoral normal tissue counterparts. Elevated H3K18la deposition activates POM121 gene transcription to accelerate MYC nuclear translocation events. Nuclear MYC dimers directly occupy CD274 (PD-L1) promoter regions to upregulate surface immune checkpoint ligand expression. Membrane-localized PD-L1 engages PD-1 receptors on tumor-infiltrating CD8+ T cells to suppress cytotoxic cytokine secretion and eliminate tumor-specific lytic capacity. Non-small cell lung carcinoma biospecimen profiling confirms positive correlation between global pan-lactylation intensity and pathological staging metrics, forming a complete metabolic-epigenetic axis governing immune surveillance suppression.
Standard Multi-Platform Workflows for Lactylation Landscape Profiling
Four interconnected analytical pipelines support systematic lactylation quantification across cell culture and tissue biospecimens. LC-MS/MS mass spectrometry acts as the reference gold standard for unbiased lactylation site identification via peptide mass shift and fragment ion sequencing. Antibody microarray systems enable high-throughput comparative lactylation quantification across parallel compound-treated experimental cohorts. Conventional Western blot delivers rapid semi-quantitative measurement of total lactylation shifts for preliminary screening workflows. Immunoprecipitation coupled with liquid chromatography-mass spectrometry leverages pan-lactylation antibodies to enrich all lactylated peptide pools for untargeted proteomic mapping. Multiplex IHC and immunofluorescence visualize spatial lactylation gradients within heterogeneous tumor lesions relative to infiltrating immune cell populations.
Unique Research Value of Pan-L-Lactyl Lysine Broad-Spectrum Antibodies
Site-specific modification antibodies only target single fixed lactylated polypeptide sequences, while pan-lactylation reagents recognize all lactylated lysine residues independent of surrounding amino acid backbones. This universal binding trait enables unbiased full-proteome lactylation profiling without prior knowledge of target protein identities. In comparative Western blot screening, pan-lactylation antibodies quantify total lactylation fluctuations under glycolysis-modulated culture environments. Immunoprecipitation workflows deploy these reagents to capture complete lactylated proteomes for downstream novel substrate discovery via mass spectrometry. FFPE tissue immunohistochemistry visualizes regional lactylation distribution patterns to correlate modification density with immune cell infiltration degrees. NSCLC mechanistic research first deployed S0B0719 pan-lactylation antibody to detect elevated tumor-wide lactylation signals before isolating H3K18la as the core functional epigenetic effector residue.
Rigorous Performance Validation of S0B0719 Pan-Lactyl Lysine Antibody
ANT BIO PTE. LTD. S0B0719 L-Lactyl Lysine Rabbit Polyclonal Antibody is manufactured with KLH-conjugated lactylated synthetic peptide immunogens and multi-step affinity purification protocols. Parallel ELISA and spot blot testing eliminate clones with cross-reactivity against acetyl, succinyl or propyl lysine PTM epitopes. Standardized validated dilution ranges include WB 1:1000–1:2000, FFPE IHC 1:1500 and immunoprecipitation incubation conditions. All production batches undergo serial tissue microarray screening to confirm consistent lot-to-lot signal uniformity with minimal non-specific background noise. Unconjugated liquid formulations buffered with glycerol maintain stable epitope binding affinity for 12 months under -20°C long-term cryogenic storage.
Diversified Basic Research Applications of S0B0719 Pan-Lactylation Antibody
Tumor immunology screening utilizes S0B0719 to map dynamic lactylation remodeling after LDHA or MCT1 inhibitor compound incubation cycles. Epigenetic chromatin research combines pan-lactylation immunoprecipitation with ChIP-seq to identify lactylation-enriched enhancer loci controlling immune checkpoint transcription. Glycolysis mechanistic cell culture assays quantify global lactylation shifts following lactate or glucose gradient stimulation. Metabolic disorder basic research profiles lactylation remodeling within adipocyte and pancreatic beta cell models under hyperglycemic culture conditions. Immune polarization co-culture experiments track lactylation fluctuations during macrophage M1/M2 transition and regulatory T cell differentiation cycles.
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANT BIO PTE. LTD., we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.
Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.
